Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of N115 on Coughing in IPF Patients
Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2023
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : N115 clinically and significantly reduced coughing/sneezing, fatigue, and increased SaO2 levels and synthesis of nasal nitric oxide. N115 Non-Steroidal Nasal Spray could be used as safe, effective treatment to help alleviate the symptoms associated with ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 05, 2021
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Post-Acute COVID-19 Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 04, 2021
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable
Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection
Details : Sodium Pyruvate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 01, 2021
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EmphyCorp N115 Reducing the Rate and Spread of COVID-19 with Nasal Nitric Oxide
Details : EmphyCorp's globally patented formula has Completed All Three Phases of Clinical Trials required by the FDA to prove safety and efficacy in treating the Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 07, 2020
Lead Product(s) : Sodium Pyruvate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable